Minimal clinically important differences in COPD lung function (Q36669438)

15 August 2017

1 reference

title

Minimal clinically important differences in COPD lung function (English)

1 reference

15 August 2017

James F Donohue

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

111-124

1 reference

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Measurement of health status. Ascertaining the minimal clinically important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Standardization of Spirometry, 1994 Update. American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Novel method for measuring effects of gas compression on expiratory flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Repeatability of Spirometry in 18,000 Adult Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Spirometric Reference Values for the 6-s FVC Maneuver *

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

The FEV1/FEV6 predicts lung function decline in adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Mortality in relation to smoking: 50 years' observations on male British doctors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Salmeterol plus theophylline combination therapy in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1081/COPD-200053377

21 January 2018

Identifiers

DOI

10.1081/COPD-200053377

1 reference

15 August 2017

1 reference